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Abstract 
The hexanucleotide repeat expansion in intron 1 of the C9orf72 gene causes amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia. In addition to the effects of the pathogenic expansion, a role of intermediate‑length alleles 
has been suggested in ALS, corticobasal degeneration and Parkinson’s disease. Due to the rarity of intermediate‑
length alleles with over 20 repeats and the geographical variability in their frequency, large studies that account for 
population stratification are needed to elucidate their effects. To this aim, we used repeat‑primed PCR and confirma‑
tory PCR assays to determine the C9orf72 repeat allele lengths in 705 ALS patients and 3958 controls from Finland. 
After exclusion of expansion carriers (25.5% of the ALS patients and 0.2% of the controls), we compared the frequency 
of intermediate‑length allele carriers of 525 ALS cases and 3950 controls using several intermediate‑length allele 
thresholds (7–45, 17–45, 21–45, 24–45 and 24–30). The carriership of an intermediate‑length allele did not associate 
with ALS (Fisher’s test, all p ≥ 0.15) nor was there any association with survival (p ≥ 0.33), when we divided our control 
group into three age groups (18–65, 66–84 and 85–105 years). Carriership of two intermediate‑length alleles was 
associated with ALS, when the longer allele was ≥ 17 repeats (p = 0.002, OR 5.32 95% CI 2.02–14.05) or ≥ 21 repeats 
(p = 0.00016, OR 15.21 95% CI 3.79–61.0). Our results show that intermediate‑length alleles are a risk factor of ALS 
when present in both alleles, whereas carrying just one intermediate‑length allele was not associated with ALS or 
survival.
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Introduction
The C9orf72 hexanucleotide repeat expansion is the 
most common genetic cause of amyotrophic lateral 
sclerosis (ALS) and frontotemporal dementia (FTD) in 
populations of European descent [7, 16, 21]. Pathological 
expansions are usually hundreds to thousands of repeats 
in length [2, 25] and the expansion can exhibit somatic 
mosaicism [2]. The minimum pathogenic repeat length is 
unknown, but the threshold of 30 repeats has been com-
monly used. This threshold might be underestimated 
since we recently found that about 0.4% of aged Finns 
carried 30–45 repeat alleles and these individuals had no 
apparent increase in the frequency of neurodegenerative 
or psychiatric diseases [13].
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There are contradictory reports on the effects of 
intermediate-length alleles under 30 repeats. For exam-
ple, C9orf72 intermediate-length alleles were reported 
to be associated with a higher risk of neuropsychiatric 
symptoms but not directly with various neurodegenera-
tive diseases including ALS [18]. However, two recent 
large meta-analyses found an association between ALS 
and 24–30 repeat alleles [5, 12]. The latter study also 
showed a different frequency of the repeats between the 
northern and southern European populations [12]. The 
comparison of different studies on the effects of interme-
diate-length alleles is complicated by the varying inter-
mediate-length allele thresholds. The different thresholds 
have been justified in many ways, e.g. association with 
the same risk haplotype as expansions (≥ 7 repeats) [24], 
effects on DNA methylation and gene expression (7–24 
and 17–29 repeats) [3, 9] and associations with neurode-
generative diseases (e.g. 17–30, 20–22, 20–30, 24–30) [3, 
10, 12, 20].
Here, we assessed the length of C9orf72 hexanucleo-
tide repeat alleles in 705 ALS patients and 3958 controls, 
tested their association with ALS and effect on sur-




We assessed the length of C9orf72 hexanucleotide repeat 
alleles in 773 ALS cases, 405 of whom were included in 
a previous genome-wide association study and in the 
discovery study of C9orf72 [15, 21]. The C9orf72 repeat 
alleles were newly genotyped in 2019–2020 for all sam-
ples. There were 177 (23%) familial ALS cases and 596 
apparently sporadic cases. The patients’ mean age-of-
onset was 58  years and 51% were females. The patients 
were recruited at the Department of Neurology, Hel-
sinki University Hospital, that receives referrals from 
neurologists throughout Finland. After exclusion of ALS 
cases with non-Finnish ancestry (n = 15) on the basis of 
patients’ self-reported birth-places and related individu-
als (n = 46, > 0.185 proportion identity-by-descent), there 
were 712 ALS cases remaining for the present study.
Our control group consisted of individuals from six 
cohorts. We have previously determined the C9orf72 
hexanucleotide repeat lengths in four cohorts and the 
cohort descriptions have been previously published [13]. 
In brief, the Vantaa 85+ study consists of 553 individu-
als of at least 85 years of age, who were living in the city 
of Vantaa, Finland on April 1st 1991 (DNA available in 
486). The Helsinki Birth Cohort Study (HBCS) originally 
consisted of 8760 individuals born in Helsinki in 1934–
1944, and a random subsample of 2003 individuals was 
neurologically assessed and underwent DNA extraction 
in 2001 (DNA was available in 1651 individuals for the 
present study). The Helsinki Businessmen study (HBS) 
included men with high socioeconomic status who were 
born in 1919–1934 and in 2002–2003, 672 individuals 
who lived at home were randomly selected for analyses 
(DNA was available in 666). The DEBATE study was orig-
inally a random sample of 4800 individuals from Helsinki 
out of whom 400 home-living individuals with stable car-
diovascular disease were randomly selected for further 
studies in 2000 (DNA was available for 375). We excluded 
one individual diagnosed with ALS from these cohorts, 
which decreased the number of controls from the origi-
nal 3142 to 3141.
The first of the new control cohorts is the PLASTICITY 
cohort [11], which consists of originally 1196 individuals 
born in 1971–74 in the Helsinki metropolitan area who 
had at least one predefined pre- or perinatal risk factor 
(e.g. birth weight ≤ 2000  g, Apgar score < 7, respiratory 
distress syndrome, diabetic mother, septic infection). At 
the age of 40 years, a survey using a mailed questionnaire 
about neurodevelopmental symptoms was conducted 
and 509 subjects responded (DNA available in 433). The 
second new control cohort includes 400 healthy blood 
donors aged 18–65 years at the time of study participa-
tion [17, 19], who were recruited in Northern Ostro-
bothnia (n = 102), Kainuu (n = 85), North Savo (n = 61), 
Pirkanmaa (n = 152) (DNA available in 400).
Genotyping
We extracted DNA using standard methods from periph-
eral blood leukocytes (5 cohorts) or saliva (PLASTICITY 
cohort). We assessed the C9orf72 hexanucleotide repeat 
alleles as previously described [21] with minor modifica-
tions [13]. In brief, for all samples, we first assessed repeat 
lengths using repeat-primed PCR (RP-PCR) followed 
by capillary electrophoresis and the results were visual-
ized using the GeneMapper software v6 (ThermoFisher). 
Then, for samples with a putative expansion (including all 
samples with ≥ 20 repeats) or unclear zygosity, we per-
formed over-the-repeat PCR. Samples that showed the 
typical saw tooth pattern in RP-PCR and did not produce 
longer amplicon in over-the-repeat PCR were catego-
rized as expansions. The longest non-expanded (amplifi-
able) discrete allele we could detect was 45 repeats, and 
we used it as the expansion threshold [13]. Examples of 
RP-PCR capillary electrophoresis chromatograms and 
over-the-repeat PCR analyses are in Additional file  1: 
Supplementary Figure 1.
We used rs3849942 allele A as a marker for the C9orf72 
risk haplotype [2]. Samples from HBS (n = 669), PLAS-
TICITY (n = 444) and DEBATE (n = 360) cohorts were 
genotyped with Illumina Global Screening Array 24v2-3, 
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Vantaa85+ (n = 512) with Illumina HumanCNV370 
array, HBCS (n = 1643) with Illumina 610k array and 
ALS cases (n = 803) with Affymetrix Axiom custom SNP 
array. Genotyping data underwent standard per-sample 
and per-variant quality control steps [1].
Statistics
We used Fisher’s exact test to test for differences in 
the frequency of intermediate-length allele carriers 
between individuals with ALS and controls. We used the 
Cochran–Armitage trend test to estimate linear trends 
between the frequency of intermediate-length allele 
carriers and different age groups as implemented in the 
CATT package (Du and Hao 2017) in R version 3.5.2 (R 
Core Team 2017). Since there is no established thresh-
old for intermediate-length alleles, in the main analysis 
we tested several thresholds with decreasing allele fre-
quency: (1) 7–45 repeats, (2) 17–45 repeats, (3) 21–45 
repeats, (4) 24–45 repeats and (5) 24–30 repeats. Since 
it can be assumed that the effect of the expansion over-
shadows any possible effects of an intermediate-length 
allele, we excluded all expansion carriers from the main 
analyses.
We calculated the statistical power of our study using 
the genpwr package (Moore, Jacobson 2019) as imple-
mented in R version 3.5.2 (Additional file 1: Supplemen-
tary Table 1).
Results
C9orf72 hexanucleotide repeat expansion 
and intermediate‑length alleles in the Finnish cohorts
We successfully genotyped 705/712 (99.0%) of the ALS 
patients and 3958/3993 (99.1%) of the controls. There 
were 180 (25.5%) ALS cases and 8 (0.20%) controls who 
carried the C9orf72 hexanucleotide repeat expansion and 
they were excluded from the main analyses leaving 525 
ALS cases and 3950 controls.
The demographic details and C9orf72 intermediate-
length allele and expansion carrier frequencies as well as 
C9orf72 risk haplotype tagging SNP frequency in each con-
trol cohort are in Additional file 1: Supplementary Table 2.
Association of C9orf72 hexanucleotide repeat 
intermediate‑length alleles with ALS
We did not observe any significant differences in the 
frequencies of the intermediate-length allele carri-
ers between ALS patients and controls (all p ≥ 0.15) 
(Table  1). The results did not markedly change when 
the 188 individuals with an expansion were included (all 
p ≥ 0.31, Additional file  1: Supplementary Table  3). All 
intermediate-length allele carrier frequencies (without 
predefined thresholds) in cases and controls are pre-
sented in Additional file 1: Supplementary Table 4.
We made an additional analysis in individuals with 
two intermediate-length alleles. There was a statisti-
cally significant difference in the frequency of individu-
als with any two copies of intermediate-length alleles 
(7–45 repeats) between ALS (26/525, 5.0%) and con-
trols (104/3950, 2.6%) (p = 0.005, OR = 1.93 [1.19–3.02]). 
Table 2 illustrates the risk of ALS in individuals with two 
copies of the intermediate-length alleles stratified by the 
length of the longer allele. In this analysis the increased 
risk is observed when the longer allele is ≥ 17 repeats 
(Table 2). Our data is not powered to pinpoint an exact 
threshold of increased risk, all genotypes of the cases and 
controls with two copies of intermediate-length alleles 
are shown in Additional file  1: Supplementary Table  5. 
Most individuals with two intermediate-length alleles 
were compound heterozygotes, i.e. they had two different 
intermediate-length alleles. (62% of ALS cases and 66% of 
the controls, Additional file 1: Supplementary Table 5).
C9orf72 risk haplotype
The haplotype tagging SNP rs3849942 was success-
fully genotyped in 683 ALS cases and 3178 controls. 
After the exclusion of expansion carriers, the frequency 
of rs3849942 (A) carriers (marker of the risk haplo-
type) was 995/3172 (31.4%) in the controls and 182/505 
(36.0%) in ALS cases (p = 0.041, OR = 1.23 [1.01–1.50], 
χ2 test). The difference was largely driven by the higher 
number of individuals homozygous for the rs3849942 
(A) allele in ALS cases than in controls (Table  3). The 
odds ratio of homozygosity for rs3849942 (A) was 1.89 
(95% CI 1.20–2.99, p = 0.018). This association was lost, 
when individuals with intermediate-length alleles were 
excluded as there were one ALS case and four controls 
who had rs3849942 A/A genotype but no intermediate-
length allele (p = 0.51 Fisher’s test). Additional file 1: Sup-
plementary Table 4 shows the distribution of rs3849942 
(A) in carriers of each intermediate-length allele in 
ALS patients and controls. Practically all intermediate-
length allele carriers with ≥ 17 repeats were also carri-
ers of rs3849942 (A) in ALS cases and controls (with one 
exception among the 76 controls with ≥ 17 repeats and 
rs3849942 data available).
Table 1 C9orf72 hexanucleotide repeat intermediate-
length allele carriers in 525 ALS patients and 3950 controls 
after exclusion of expansion carriers
Longer allele Controls n ALS n p OR 95% CI
7–45 1293 (33%) 185 (35%) 0.26 1.12 0.92–1.36
17–45 101 (2.6%) 19 (3.6%) 0.15 1.43 0.82–2.74
21–45 66 (1.7%) 12 (2.3%) 0.29 1.38 0.67–2.59
24–45 43 (1.1%) 6 (1.1%) 0.82 1.05 0.36–2.50
24–30 30 (0.76%) 3 (0.57%) 1 0.75 0.15–2.43
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C9orf72 hexanucleotide repeat intermediate‑length allele 
distributions in different age groups
To test for a possible effect on survival presenting as a 
difference in the frequency of intermediate-length allele 
carriers in different age groups, we divided the controls 
into three age categories 18–65, 66–84 and 85–106 years. 
We did not observe a statistically significant linear trend 
between the proportion of intermediate-length allele car-
riers and age groups (Table 4). 
We did not have the power to detect differences in 
carriers of two copies of intermediate-length alleles due 
to their rarity but analyzed them for descriptive pur-
poses. This analysis showed that in the oldest age group 
(≥ 85  years) there were no individuals with two inter-
mediate-length alleles where the longer allele was ≥ 21 
repeats. The C9orf72 haplotype tagging SNP rs3849942 
homozygosity (A/A) was found in 16/436 (3.7%), 43/1688 
(2.5%) and 26/1047 (2.5%) in the age groups 18–65, 
66–84 and ≥ 85  years respectively (p = ,0.28 Cochran–
Armitage trend test).
Discussion
In our analyses, the frequencies of the C9orf72 hexanu-
cleotide repeat intermediate-length allele carriers did not 
show a statistically significant difference between Finnish 
ALS patients and controls when only the longer allele was 
considered (all p ≥ 0.15). In addition, we did not observe 
any significant differences in the frequency of carriers of 
the intermediate-length alleles in controls belonging to 
different age groups (Table 3) suggesting that carriership 
of these alleles are not subject to strong negative selec-
tion during aging. Hence, just carriership of an interme-
diate-length allele does not confer increased risk of ALS 
or play a major role in survival in the Finnish population.
However, when individuals with two copies of the 
intermediate-length alleles were studied, significant asso-
ciations were found, especially when the longer allele was 
≥ 17 repeats (Table 2). The highest homozygous number 
of repeats was 12 repeats (Additional file 1: Supplemen-
tary Table  5) indicating that most of the risk genotypes 
were compound heterozygotes. Compound heterozygote 
effect of the intermediate-length CAG-repeat alleles has 
been previously shown in spinocerebellar ataxia 3 [22]. 
The “two copy effect” was further supported by the asso-
ciation of the risk haplotype marker homozygosity with 
ALS (Table 3).
Our results suggest that in the Finnish population, car-
rying one intermediate-length allele does not significantly 
increase the risk of ALS but having two such alleles and 
one of these ≥ 17 repeats raises the odds of ALS about 
Table 2 Individuals with  two intermediate-length alleles in  525 ALS patients and  3950 controls after  exclusion 
of expansion carriers
Shorter/longer allele Controls n (%) ALS n (%) p OR 95% CI
≥ 7/≥ 7 104 (2.6%) 26 (5.0%) 0.005 1.93 1.19–3.02
7–16/7–16 94 (2.4%) 19 (3.6%) 0.098 1.57 0.90– 2.62
≥ 7/17–45 10 (0.25%) 7 (1.3%) 0.0020 5.32 1.71–15.56
≥ 7/21–45 3 (0.076%) 6 (1.1%) 0.00016 15.19 3.23–94.21
≥ 7/24–45 1 (0.025%) 4 (0.76%) 0.00085 30.26 2.99–1479
Table 3 Comparison of  rs3849942 genotypes in  505 ALS 




Controls n (%) ALS n (%) χ2
G/G 2177 (68.6%) 323 (64.0%) 1.40
G/A 910 (28.7%) 157 (31%) 0.87
A/A 85 (2.7%) 25 (5.0%) 7.51
Total 3172 505 9.77, 2df, 
p = 0.0076
Table 4 Intermediate repeat length allele frequencies 
in different age groups of controls
a Cochran–Armitage trend test. Excluded 10 individuals from whom age group 
was unknown
18–65 years 66–84 years 85–105 years p  valuea
Longer allele
 7–45 273 (31%) 656 (33%) 363 (33%) 0.46
 17–45 29 (3.3%) 44 (2.2%) 28 (2.5%) 0.33
 21–45 18 (2.1%) 29 (1.5%) 19 (1.7%) 0.62
 24–45 12 (1.4%) 17 (0.86%) 14 (1.3%) 0.92
 24–30 10 (1.1%) 9 (0.46%) 11 (1.0%) 0.85
Two 7–45 alleles 26 (3.0%) 51 (2.6%) 27 (2.5%) 0.48
Longer allele in individuals with two 7–45 alleles
 7–16 23 (2.6%) 47 (2.4%) 24 (2.2%)
 ≥ 17 3 (0.34%) 4 (0.20%) 3 (0.27%)
 ≥ 21 1 (0.11%) 2 (0.10%) 0
 ≥ 24 0 1 (0.050%) 0
N of age group 873 1973 1102
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fivefold. This is not a big increase in risk in a rare disease 
like ALS with a lifetime risk of ca. 1/400. Therefore, in 
ALS patients with two intermediate-length alleles, the 
effect of additional genetic or environmental factors is 
likely important for the disease development. It is of note, 
that one of our ALS patients who had 8/36 repeat alleles 
was also homozygous for the SOD1*D91A mutation and 
survived 14 years after diagnosis. Such a long survival is 
typical in SOD1*D91A ALS but not in C9orf72 ALS sug-
gesting that the major genetic factor modulating the clin-
ical picture was the SOD1 mutation.
Our results agree with a previous study that reported in 
Belgian ALS and FTD–ALS patients (n = 135) a significantly 
increased risk in carriers of two copies of the intermediate-
length alleles (OR 2.08, p = 0.04) [9]. Also, in a Flanders–
Belgian cohort of patients with FTD (without C9orf72 
expansion) a significant risk for homozygous carriers of the 
C9orf72 risk haplotype tagging SNP was found (OR 1.75, 
p = 0.04), which disappeared after removal of intermediate-
length allele carriers [24]. Functionally the intermediate-
length alleles have been shown to modulate expression of 
C9orf72, which may vary in different tissues [3, 9]. In nerve 
tissue the intermediate-length alleles and the risk haplotype 
tagging SNP have been shown to result in increased C9orf72 
transcription from the promoter upstream of the hexanu-
cleotide repeat, while intermediate alleles did not generate 
RNA foci or dipeptide repeat proteins that are pathogno-
monic for the C9orf72 expansion [3].
Our results are somewhat in contrast with a recent 
meta-analysis comprising 5071 ALS cases and 3747 
controls that reported an association of 24-30 repeat 
alleles with ALS with an odds ratio 4.20 (random-effects 
model p = 0.02) [12]. The association with 24–30 repeats 
was robust and the association was observed even 
when omitting one study at a time in the meta-analysis. 
Another report suggesting the pathogenicity of alleles of 
≥ 17 repeats studied autopsy-proven corticobasal degen-
eration cases (CBD) from UK and USA versus global con-
trols [3]. These intermediate-length alleles also increased 
C9orf72 expression in the human brain and in neural pro-
genitor cells [3]. Complete genotypes were not reported 
in the ALS meta-analysis, while in the CBD study 2 out of 
13 cases were compound heterozygotes for an interme-
diate-length allele. In both studies, it was assumed that 
carriership of either 24–30 repeats (ALS) or ≥ 17 repeats 
(CBD) was the main risk factor for disease. Our data 
does not support this assumption to be true in Finland. 
There are several potential explanations for our different 
results.
First, the genetics and penetrance of the intermedi-
ate-length alleles might be different in Finland versus 
other populations. All carriers of intermediate-length 
alleles of ≥ 17 repeats were also carriers of the risk 
haplotype-tagging SNP (with only one exception, Addi-
tional file 1: Supplementary Table 5), which indicates that 
the gross haplotype background is similar in Finland and 
other populations. However, there could be a protective 
factor in Finland that decreases the risk of heterozy-
gotes and allows the carrier frequencies to rise in normal 
population. It is of note that two copies of the interme-
diate-length alleles were required for increased risk in 
Belgian ALS and FTD-ALS patients, too [9]. Hence, the 
hypothetical protective factor should be widely spread in 
Europe.
Second, population stratification can confound the 
analyses. The observed ethnic and geographic differences 
in the intermediate-length allele frequencies [12, 13] may 
potentially result in spurious associations due to popula-
tion stratification. The discrepancy between our results 
and previous reports seem to be largely driven by the 
higher frequency of the long intermediate-length alleles 
(≥ 20 repeats) in our Finnish controls. The frequencies 
of the long intermediate-length alleles in ALS and CBD 
cases show much less dispersion than controls between 
populations as illustrated in Fig.  1. Therefore, studies 
using multinational cohorts need to carefully account 
for population stratification and, additionally, use suffi-
ciently large subcohorts to ensure that rare alleles can be 
captured.
Third, different genotyping methodology of the 
C9orf72 hexanucleotide repeat can affect results. It is 
well-known that genotyping of the C9orf72 hexanu-
cleotide repeat can be challenging, as the large size and 
high GC content of the C9orf72 expansion does not 
allow full polymerization during PCR. Even accredited 
laboratories report different genotypes from the same 
sample [6]. For differentiating homozygotes and het-
erozygotes in unclear samples, we used an additional 
confirmatory PCR method (Additional file  1: Supple-
mentary Figure  1). There may also be slight inconsist-
encies in the determination of the exact lengths of the 
longer alleles (e.g. 23 vs. 24 repeats) with RP-PCR. For 
this reason in our analyses the smallest range of repeat 
length was seven (24–30 repeats). Meta-analyses rely 
on previous studies often with varying genotyping 
methodologies, which can make the harmonization of 
data difficult. The different sources of DNA is another 
possible confounding factor, as the use of blood ver-
sus brain or lymphoblastoid cell line derived DNA may 
cause significant bias [2, 8] although not yet system-
atically studied in C9orf72 intermediate-length alleles. 
Huntington’s disease CAG-repeat represents a case in 
which the size of an intermediate allele with 34 repeats 
has been shown to increase in serially passaged lymph-
oblastoid cell lines [4].
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Our study’s strength is the focus on Finnish individu-
als, which decreases the effects of population stratifica-
tion and allows a sufficiently large number of longer 
intermediate-length allele carriers for comparisons 
because these alleles are relatively common in this popu-
lation [13]. However, it also affects the generalizability of 
Fig. 1 The frequencies of non‑expanded long C9orf72 hexanucleotide repeat intermediate‑length alleles in three previous case‑control studies in 
comparison with Finnish ALS cases and controls. ≥ 17 repeat alleles were found in 3.6% of the Finnish ALS cases, 2.6% of the controls (present study) 
and in 3.7% of cases with autopsy‑proven corticobasal degeneration (CBD) as compared to 0.52% of the Global controls [3] and 1.9% for UK 58 Birth 
cohort [2]. The majority of cases were from three centers from USA and UK, while the controls were from a global study [23]. Allele frequencies for 
58BC were obtained as personal written communication from Professor Simon Mead. Each ≥ 17 allele is presumed to be carried by one individual. 
≥ 21 repeat alleles were found in 2.3% of the Finnish ALS cases and 1.7% of the controls (present study), and in 1.7% of CBD cases. These alleles were 
not reported in the Global controls [23]. 24–30 repeat alleles were found in 0.57% of the Finnish ALS cases and 0.76% of controls (present study),and 
in 0.5% of CBD cases and in 0.4% of ALS cases vs. 0.03% of controls in a recent meta‑analysis [10]
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our results. Based on our assessment of C9orf72 repeat 
length Finns have more 2–6 repeat alleles, less 7–19 
repeat alleles and again more ≥ 20 repeat alleles than the 
general European population. The risk haplotype (and 
intermediate-length allele) tagging rs3849942 (A) is less 
common in Finland as compared to non-Finnish Europe-
ans and reflects the lower frequency of the 7–19 repeat 
alleles in Finns. Therefore, we cannot exclude the possi-
bility of unknown selection factors facilitating the enrich-
ment of ≥ 20 alleles in the Finnish population.
Our study has also limitations. The controls and ALS 
cases were genotyped for rs3849942 using different plat-
forms and different genotyping centers, which can lead 
to slight differences in allele frequencies. However, we 
do not believe this to be an important source of error, 
since the allele frequencies in our controls were consist-
ent with the Finnish samples of the gnomAD database v.3 
[14]. Moreover, we had whole-genome sequencing data 
on ca. 300 ALS cases that had also been genotyped for 
rs3849942 and the concordance of genotypes was 100%. 
Furthermore, RP-PCR, which we used to assess C9orf72 
repeat lengths, is accurate in detecting expansions and 
sizing most alleles, but like with other genotyping meth-
ods, the longer the allele, the harder it is to assess the 
exact length. Given that rs3849942 genotypes and the 
C9orf72 repeat lengths correlated well, the number of 
wrongly assessed genotypes is likely small, and should 
not affect the conclusions of the study. We genotyped 
all cohorts except one from peripheral blood-derived 
DNA and age of the DNA samples varied. The cohort 
with saliva-derived DNA had the lowest genotyping suc-
cess rate (97.2% vs. 98.9–99.4% in other cohorts), but the 
genotype distribution did not differ significantly from the 
other cohorts suggesting that the different source of DNA 
should not cause meaningful bias to the results. On the 
other hand, although we did not observe any marked dif-
ference in the C9orf72 allele distribution of our younger 
and older control individuals, we cannot exclude small 
effects on survival, undetectable with the present sample 
size. A larger study is required to analyze small effects on 
survival and to test also survival in carriers of two copies 
of intermediate-length alleles and homozygotes for the 
C9orf72 risk haplotype tagging SNPs.
Conclusions
Our data indicate that the C9orf72 intermediate-length 
alleles increase the risk of ALS when present in two cop-
ies, carriership of only one intermediate-length allele 
is not associated with ALS or survival in the Finnish 
population. The clinical significance of the intermediate-
length alleles should be critically re-assessed in carriers 
of one and two copies of these alleles.
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